Engagement of Canadian Patients with Rare Diseases and Their Families in the Lifecycle of Therapy: A Qualitative Study

Andrea Young (), Devidas Menon, Jackie Street, Walla Al-Hertani and Tania Stafinski
Additional contact information
Andrea Young: University of Alberta
Devidas Menon: University of Alberta
Jackie Street: University of Adelaide
Walla Al-Hertani: University of Calgary
Tania Stafinski: University of Alberta

The Patient: Patient-Centered Outcomes Research, 2018, vol. 11, issue 3, No 9, 353-359

Abstract: Abstract Introduction Patient involvement is increasingly recognized as critical to the development, introduction and use (i.e. the lifecycle) of new and effective therapies, particularly those for rare diseases, where natural histories and the impact on patients and families are less well-understood than for common diseases. However, little is known about how patients and families would like to be involved during the lifecycle. Objective The aim of this study was to explore ways in which Canadian patients with rare diseases and their families would like to be involved in the lifecycle of therapies and identify their priorities for involvement. Methods Patients with rare diseases and their families were recruited to participate in two deliberative sessions, during which concepts related to decision-making uncertainty and the technology lifecycle were introduced before eliciting input around ways in which they could be involved. This was followed by a webinar, which was used to further identify opportunities for involvement. The data were then analyzed qualitatively using eclectic coding. Results Patients and families identified opportunities that fell into three goals: (1) incorporation of their ‘lived experience’ in coverage decision making (i.e. decisions by governments on funding new therapies); (2) improved care for patients; and (3) greater awareness of rare diseases, with the first being a priority. Conclusions Opportunities for patients and families to contribute their ‘lived experience’ are needed throughout the orphan drug lifecycle, but the ideal mechanisms for providing this input have yet to be determined.

Date: 2018
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
http://link.springer.com/10.1007/s40271-017-0293-1 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:patien:v:11:y:2018:i:3:d:10.1007_s40271-017-0293-1

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40271

DOI: 10.1007/s40271-017-0293-1

Access Statistics for this article

The Patient: Patient-Centered Outcomes Research is currently edited by Christopher I. Carswell

More articles in The Patient: Patient-Centered Outcomes Research from Springer, International Academy of Health Preference Research
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().